| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5976573 | SANOFI AVENTIS US | Aqueous-based pharmaceutical composition |
Jul, 2016
(7 years ago) | |
| US6143329 | SANOFI AVENTIS US | Aqueous-based pharmaceutical composition |
Jul, 2016
(7 years ago) | |
| US7977045 | SANOFI AVENTIS US | Aqueous-based pharmaceutical composition |
Jul, 2016
(7 years ago) | |
Nasacort Aq is owned by Sanofi Aventis Us.
Nasacort Aq contains Triamcinolone Acetonide.
Nasacort Aq has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Nasacort Aq are:
- US5976573
- US6143329
- US7977045
Nasacort Aq was authorised for market use on 20 May, 1996.
Nasacort Aq is available in spray, metered;nasal dosage forms.
Nasacort Aq can be used as treatment of nasal symptoms of seasonal and perennial allergic rhinitis in adults and children two years of age and older.
The generics of Nasacort Aq are possible to be released after 03 July, 2016.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 19, 2011 |
Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient
Market Authorisation Date: 20 May, 1996
Treatment: Treatment of nasal symptoms of seasonal and perennial allergic rhinitis in adults and children two years of age and older
Dosage: SPRAY, METERED;NASAL
NASACORT AQ family patents
